NCT07697222 SPSIPB Versus SAPB for Postoperative Analgesia After Minimally Invasive Repair of Pectus Excavatum
| NCT ID | NCT07697222 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marmara University |
| Condition | Pectus Excavatum |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-06-22 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2026-06-22 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational cohort study will compare postoperative analgesic outcomes in patients undergoing minimally invasive repair of pectus excavatum. Participants will be grouped according to the regional analgesia technique applied as part of routine clinical care: serratus posterior superior intercostal plane block or serratus anterior plane block. The primary outcome will be total opioid consumption during the first 24 hours after surgery. Secondary outcomes will include postoperative pain scores, rescue analgesic requirement, opioid-related adverse effects, patient satisfaction, mobilization time, and length of hospital stay.
Eligibility Criteria
Inclusion Criteria: * Patients aged 15 to 25 years * Diagnosis of pectus excavatum * Scheduled to undergo minimally invasive repair of pectus excavatum under general anesthesia * Receipt of either bilateral serratus posterior superior intercostal plane block or bilateral serratus anterior plane block as part of routine perioperative analgesic care * Written informed consent obtained from the patient or, for patients younger than 18 years, from a legal guardian Exclusion Criteria: * Refusal to participate in the study * Contraindication to regional anesthesia * Known allergy to local anesthetics or study analgesic medications * Chronic opioid use * Pre-existing chronic pain syndrome * Coagulopathy or use of anticoagulant therapy that contraindicates regional block application * Local infection at the block injection site * Neurological or psychiatric condition that may interfere with pain assessment * Incomplete perioperative or postoperative data * Conversion to another surgical technique or major intraoperative complication requiring a change in the routine analgesic protocol
Contact & Investigator
Cem Özdemir, MD
STUDY CHAIR
Marmara University
Frequently Asked Questions
Who can join the NCT07697222 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 25 Years, studying Pectus Excavatum. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07697222 currently recruiting?
Yes, NCT07697222 is actively recruiting participants. Contact the research team at suskungeveze.cem@gmail.com for enrollment information.
Where is the NCT07697222 trial being conducted?
This trial is being conducted at Istanbul, Turkey (Türkiye).
Who is sponsoring the NCT07697222 clinical trial?
NCT07697222 is sponsored by Marmara University. The principal investigator is Cem Özdemir, MD at Marmara University. The trial plans to enroll 80 participants.